Biallelic mutations of the CEBPA gene (CEBPA bi) define a distinct entity associated with
favorable prognosis; however, the role of monoallelic mutations (CEBPA sm) is poorly …

Mutations in CCAAT/enhancer binding protein α (CEBPA) are seen in 5% to 14% of acute
myeloid leukemia (AML) and have been associated with a favorable clinical outcome. Most …

Mutations of CCAAT/enhancer–binding protein alpha (CEBPA mu) are found in 10% to 15%
of de novo acute myeloid leukemia (AML) cases. Double-mutated CEBPA (CEBPA dm) is …

Biallelic CEBPA mutations are associated with favorable outcomes in acute myeloid
leukemia (AML). We evaluated the clinical and biologic implications of CEBPA-basic leucine …

Purpose CEBPA mutations are found as either biallelic (bi CEBPA) or monoallelic (mo
CEBPA). We set out to explore whether the kind of CEBPA mutation is of prognostic …

CEBPA mutations have been associated with improved outcome in adult acute myeloid
leukemia (AML). We evaluated the prevalence and prognostic significance of CEBPA …

We evaluated concurrent gene mutations, clinical outcome, and gene expression signatures
of CCAAT/enhancer binding protein alpha (CEBPA) double mutations (CEBPA dm) versus …

Mutations in CCAAT/enhancer binding protein α (CEBPA) occur in 5–10% of cases of acute
myeloid leukemia. CEBPA-double-mutated cases usually bear biallelic N-and C-terminal …

Purpose The transcription factor CCAAT/enhancer binding protein-α (CEBPA) is crucial for
normal myeloid differentiation. Mutations in the CEBPA gene are found in subsets of patients …

Purpose: The transcription factor CCAAT/enhancer binding protein α, encoded by the
CEBPA, is crucial for the differentiation of immature granulocytes. Mutation of the CEBPA …